Logo
x

Search

Subscribe Now

Plaque Psoriasis

PharmaShots Interview: Dermavant’s Philip Brown Shares Insight on the P-III (PSOARING 3) Study of Tapinarof

PharmaShots Interview: Dermavant’s Philip Brown Shares Insight on the P-III (PSOARING 3) Study of Tapinarof

  • March 15, 2022
Innovent Reports the First Patient Dosing in P-II CIBI112A201 Trial of IBI112 for the Treatment of Plaque Psoriasis

Innovent Reports the First Patient Dosing in P-II CIBI112A201 Trial of IBI112 for the Treatment of Plaque Psoriasis

  • September 24, 2021
Novartis Cosentyx (secukinumab) Receives NICE Recommendation for Patients with Plaque Psoriasis

Novartis Cosentyx (secukinumab) Receives NICE Recommendation for Patients with Plaque Psoriasis

  • September 3, 2021
UCB's Bimzelx (bimekizumab) Receives EC's Approval for the Treatment of Moderate to Severe Plaque Psoriasis

UCB's Bimzelx (bimekizumab) Receives EC's Approval for the Treatment of Moderate to Severe Plaque Psoriasis

  • August 24, 2021
Dermavant Reports the US FDA's Acceptance of NDA for Tapinarof Cream to Treat Plaque Psoriasis

Dermavant Reports the US FDA's Acceptance of NDA for Tapinarof Cream to Treat Plaque Psoriasis

  • August 11, 2021
UCB Presents Two-Year Data of Bimekizumab in BE BRIGHT Trial for the Treatment of Moderate to Severe Plaque Psoriasis at AAD 2021

UCB Presents Two-Year Data of Bimekizumab in BE BRIGHT Trial for the Treatment of Moderate to Severe Plaque Psoriasis at AAD 2021

  • August 9, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.